### Internal request

In response to the FDA approval of rituximab-pvvr for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy, the panel voted on the addition of rituximab-pvvr.

Consider the inclusion of rituximab-abbs and rituximab-pvvr as appropriate substitutes for rituximab in all subtypes of B-cell lymphomas.

### Panel Discussion/References

Based upon the recent FDA approval and panel discussion, the consensus was to include rituximab-abbs and rituximab-pvvr as appropriate substitutes for rituximab in all subtypes of B-cell lymphomas with the following statement, “An FDA-approved biosimilar is an appropriate substitute for rituximab.”


### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
</tbody>
</table>